Production of genetically engineered mice with higher efficiency, lower mosaicism, and multiplexing capability using maternally expressed Cas9

Takayuki Sakurai1,2*, Akiko Kamiyoshi1,2, Hisaka Kawate1,2, Satoshi Watanabe3, Masahiro Sato4 & Takayuki Shindo1,2

The CRISPR/Cas9 system is widely used to generate gene-edited animals. Here, we developed an efficient system for generating genetically modified mice using maternal Cas9 from Cas9 transgenic mice. Using this system, we achieved lower mosaicism and higher rates of knock-in success, gene-editing, and birth compared to the similar parameters obtained using exogenously administered Cas9 (mRNA/protein) system. Furthermore, we successfully induced simultaneous mutations at multiple loci (a maximum of nine). Our novel gene-editing system based on maternal Cas9 could potentially facilitate the generation of mice with single and multiple gene modifications.

Genetically modified (GM) organisms, with specific genes altered (added or ablated), are widely used for modeling human and animal diseases. They are particularly useful for understanding the molecular mechanisms of diseases and for the development of novel disease treatments1,2. In the past three decades, GM animals have been created by microinjecting transgenes into zygote nuclei (zygote microinjection) or by injecting the blastocoel with GM embryonic stem cells engineered to exhibit altered expression of a specific gene by gene targeting technology3,4. It is now easier than ever to create GM animals by using the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated-9 (CRISPR/Cas9) genome editing system5–12 due to its wide applicability, high efficiency, and design simplicity13–15. The most commonly used approach for generating GM animals with the CRISPR/Cas9 system is by microinjecting the CRISPR/Cas9 components, such as Cas9 DNA, mRNA or protein, guide RNA (gRNA), and, in some cases, a homology direct repair (HDR) template, into the zygote16–20. gRNA efficiently induces Cas9-mediated double strand breaks at desired target sites, which stimulate DNA repair by at least two distinct mechanisms: non-homologous end joining and HDR21–23.

However, the zygote microinjection-based genome editing system has inherent problems. For example, frequent mosaicism for inducing insertion/deletion (indel) at the target locus is seen in almost all individuals obtained using this approach24–26. Given that transcription and translation are suppressed in mouse zygotes, the translation of the introduced Cas9 DNA/mRNA into its active enzymatic form is likely delayed until after the first cell division, causing unequal genome editing in individual blastomeres27. It has been recently reported that direct Cas9 protein expression in early-stage mouse zygotes reduces the occurrence of mosaic mutations28. In addition, the amount of CRISPR/Cas9 reagents injected into the zygote is limited as high volumes are often associated with developmental arrest of the embryos29, reducing the possibility of simultaneous modifications in multiple genes using the CRISPR/Cas9 system30. Previously, we tackled these problems by generating systemically Cas9-expressing transgenic (Tg) (sCAT) mice that produce maternal Cas9 (maCas9), which exhibits nuclease activity, during oogenesis30. Microinjecting
grNA constructs into the cytoplasm of sCAT zygotes resulted in the one-step generation of individuals carrying mutations in multiple genes, with grRNA decomposing around the 2-cell stage30.

One merit of utilizing maCas9 to generate GM animals is that they would exhibit less mosaicism for indel mutations because active Cas9 proteins would exist in the embryos only for a limited time. Furthermore, because the maCas9 approach does not require Cas9 mRNA (or protein) upon zygote microinjection, maCas9 zygotes may be injected with greater amounts of grRNA and, in some cases, with more DNA fragments. However, we found that grRNA microinjection into sCAT zygotes failed to reduce the mosaicism significantly30. We believe that this failure was probably due to the variable efficiencies of the grRNA preparations, which meant that the amounts of microinjected grRNAs differed among zygotes. This circumstance complicated the evaluation of maCas9-based genome editing. Furthermore, it has recently been reported that the delivery of CRISPR/Cas9 reagents into the zygote by electroporation (EP) provides higher genome editing efficiency than that achieved by zygote microinjection31–33.

In this study, we reevaluated the potential benefits of the maCas9-based genome editing system via the in vitro EP of sCAT zygotes with grRNAs and DNA fragments instead of zygote microinjection. First, we examined whether in vitro EP enabled the simultaneous and unbiased introduction of RNAs into zygotes and whether the efficiencies of inducing indel and knock-in (KI) mutations in maCas9 zygotes after in vitro EP with grRNA(s) alone were comparable to those in wild-type (WT) zygotes electroporated with grRNAs and Cas9 mRNA (or protein). We also examined whether the indel introduction efficiency could be regulated by the concentration of grRNA introduced into sCAT zygotes and whether there were fewer mosaic mutations in scAT zygotes electroporated with grRNA alone than in WT zygotes electroporated with Cas9 mRNA and grRNA. Finally, we examined whether multiple (up to 10) genes can be knocked out simultaneously in sCAT zygotes electroporated with multiple grRNAs. This study shows that maCas9-based gene-editing is a potential alternative system for generating animals with various single and multiple gene modifications.

Results

In vitro EP prompts synthetic mRNA uptake by zygotes with little variation between individuals.

We first examined whether the in vitro EP of zygotes in the presence of an external substance (i.e., synthetic mRNA, such as EGFP A95 mRNA) permits incorporation of the latter into zygote cytoplasm and assessed the extent of variation in incorporation efficiency between individuals. We prepared 5 μL aliquots of EP solution containing 0, 20, 100, or 200 ng/mL EGFP A95 mRNA and placed them between two electrodes on a plate. Zygotes derived from in vitro fertilization (IVF; 8–10 embryos/group) were then introduced into the drop and immediately subjected to in vitro EP. These experiments were carried out twice. The EP-treated zygotes were then allowed to develop into 2-cell embryos after being cultured for 12 h in vitro. In these developing 2-cell embryos, the average EGFP A95-derived fluorescence intensity, measured using a fluorescence microscope, did not vary among embryos of different groups (Fig. 1a), and the fluorescence intensity was directly proportional to the amount of EGFP A95 mRNA used (Fig. S1b). In contrast, variable fluorescence intensities were observed among embryos when the zygotes were microinjected with 20 ng/μL EGFP A95 mRNA (Fig. S1c). These results indicate a close relationship between the amount of mRNA incorporated into zygotes and the rate at which the mRNA is translated into proteins in the resultant embryos. Next, we used in vivo EP to examine the possible utility of maCas9 for improving the overall efficiency of genome editing using sCAT-derived zygotes.

Regulation of indel induction efficiency by varying concentration of grRNA introduced into sCAT zygotes.

Maximal accumulation of maCas9 in oocytes has been hypothesized to occur during folliculogenesis32. Thus, the amount of maCas9 in each ovulated oocyte should be sufficient for genome editing and individual differences should be quite small, in which case, it may be possible to regulate the efficiency of indel generation by changing the amount of grRNA introduced into the oocytes. Therefore, we examined the relationship between grRNA concentration and the degree of indel generation using the experimental procedure outlined in Fig. 1a: self-derived zygotes were subjected to in vitro EP in the presence of 25, 80, or 200 ng/mL grRNA targeting the endothelin1 (Et1) gene (hereafter referred to as Et1-grRNA), and after EP, the treated zygotes were allowed to develop into blastocysts in vitro. The blastocysts were lysed to isolate genomic DNA for the PCR-based amplification of the target region recognized by Et1-grRNA (Figs. 1b and S2a). The resulting PCR products were then cloned into the TA cloning vector for sequencing; typical examples are shown in Fig. 1b. When Et1-grRNA was introduced at a concentration of 25 ng/μL (Fig. 1c), 8% of +/+ blastocysts and 9% of Tg/+ blastocysts had two WT alleles, whereas 8% and 18% of +/+ blastocysts and Tg/+ blastocysts had indels in both alleles (hereafter referred to as “bi-allelic” mutations), respectively. Moreover, 84% of the +/+ blastocysts and 73% of the Tg/+ blastocysts carried indels in only one of the two alleles (hereafter referred to as “mono-allelic” mutations), and there was no significant difference between the percentage of +/+ and Tg/+ blastocysts with indels per genome. Similar results were obtained when Et1-grRNA was introduced at concentrations of 80 and 200 ng/mL. However, in the latter case, there were no +/+ or Tg/+ blastocysts carrying WT alleles and the fraction carrying mono-allelic mutations decreased to 47–57%, whereas the fraction carrying bi-allelic mutations increased to 47–75% (Fig. 1c). The efficiency of indel induction per genome positively correlated with the amount of grRNA introduced by in vitro EP (Fig. 1b), and there was no significant difference in the fraction of +/+ and Tg/+ blastocysts with indels per genome, suggesting that it may be possible to regulate the rate of indel induction via the concentration of grRNA introduced into zygotes carrying maCas9. We assessed this hypothesis by producing Et1 gene-modified mice (Fig. S3). Briefly, sCAT-derived zygotes were subjected to in vitro EP with 25 or 200 ng/mL Et1-grRNA (Fig. S3a) and transferred into the oviducts of pseudopregnant recipient females one day after cultivation to obtain pups (Fig. S3b). Phenotypic alterations in the pups (e.g., craniofacial defects) and the presence of possible mutations in the target sequence recognized by Et1-grRNA were assessed (Fig. S3c). As expected, no Et1
knockout (KO) pups with craniofacial defects were obtained when EP was carried out with 25 ng/µL Et1-gRNA, with the efficiency of indel induction ranging between 57 and 67%. In contrast, when EP was carried out with 200 ng/µL Et1-gRNA, 29–56% of pups were identified as Et1 KO, and all of them carried indels.
Highly efficient genome editing in maCas9 zygotes electroporated with 200 ng/µL gRNA. We compared the efficiency of genome editing in maCas9 zygotes and non-maCas9 zygotes co-administered with Cas9 mRNA/gRNA or Cas9 protein/gRNA (Fig. 2a). First, maCas9 zygotes were electroporated in the presence of 200 ng/µL Et1-gRNA and transferred to recipient females to develop. On days 12.5–13.5, fetuses with craniofacial defects (Fig. 2b) were deemed to be Et1 KO fetuses, as described in a previous gene targeting-based study. All fetuses were subjected to genotyping for the presence of the Cas9 transgene, PCR of the target region recognized by Et1-gRNA, and sequencing of the PCR products cloned into a TA cloning vector. Typical results obtained from this experiment are shown in Fig. S4. Control non-maCas9 zygotes derived from the IVF of oocytes (+/+) with sCAT spermatozoa (+/+) were subjected to in vitro EP with 15 ng/µL Cas9 mRNA/200 ng/µL Et1 gRNA, 100 ng/µL Cas9 mRNA/200 ng/µL Et1-gRNA, 5 ng/µL Cas9 protein/200 ng/µL Et1-gRNA, or 50 ng/µL Cas9 protein/200 ng/µL Et1-gRNA (Fig. 2a). The treated embryos were then transferred into recipient females to obtain mid-gestational fetuses, and molecular biological analysis was performed as described above (Fig. 2c). Of the fetuses derived from maCas9 zygotes (Fig. 2a, upper panel), 55% of the +/- fetuses and 50% of the Tg/+ fetuses had Et1 KO phenotype, whereas nearly 100% had indels, as expected (Figs. 1c and S3c). These results appear to correspond to those obtained from the non-maCas9 zygotes electroporated with 100 ng/µL Cas9 mRNA/200 ng/µL Et1-gRNA or 50 ng/µL Cas9 protein/200 ng/µL Et1-gRNA (Fig. 2c), since the rates of KO incidence in these groups were both high and not significantly different. Next, we checked for possible off-target effects induced by Et1-gRNA in Et1 KO fetuses (12 +/- fetuses and 9 Tg/+ fetuses). No mutations in the target regions listed as those with higher probability have been observed (Table S1). We also compared the efficiency of genome editing in maCas9 and non-maCas9 zygotes after co-administering Cas9 mRNA/gRNA or Cas9 protein/gRNA, both of which target Tyr (Fig. S5a). The incidence rates of Tyr KO phenotype (evaluated by eye pigment deficiency; Fig. S5b) and indel induction were relatively high and not significantly different (Fig. S5c) among the three groups (47–68% and 75–84%, respectively).

Low mosaic mutation rate in scAT zygotes electroporated with 200 ng/µL gRNA. To examine mosaic mutation efficiency in maCas9 zygotes, we compared the distribution of indel modifications in mid-gestational fetuses derived from maCas9 zygotes electroporated with 200 ng/µL gRNA and from non-maCas9 zygotes electroporated with Cas9 mRNA (100 ng/µL)/gRNA (200 ng/µL) or Cas9 protein (50 ng/µL)/gRNA (200 ng/µL) (Fig. 2d). Et1 KO fetuses (9–15 per group) were selected from each group (Fig. 2c). For the Tg/+ samples, the nine fetuses shown in Fig. 2c and five fetuses shown in Fig. S3 were combined and analyzed (Fig. 2d). The percentages of maCas9 zygote-derived fetuses (+/+) with one, two, or three indels after EP with 200 ng/µL Et1-gRNA were 25, 58, and 17%, respectively. Similarly, the percentages of Tg/+ fetuses with one, two, or three indels were 14, 79, and 7%, respectively (Fig. 2d), whereas the percentages of Tg/+ fetuses with one, two, or three/four indels after EP with Cas9 mRNA/Et1-gRNA were 9, 18, and 73% respectively (Fig. 2d). Moreover, the percentages of fetuses with one, two, or three indels after EP with Cas9 protein/Et1-gRNA were 13, 67, and 20%, respectively (Fig. 2d). There were no significant differences in the percentages of indel generation between sCAT +/- (Et1-gRNA), Tg/+ (Et1-gRNA), and +/- (Cas9 protein/Et1-gRNA) groups (Fig. 2d). However, significant differences were observed in indel percentages in sCAT +/- (Et1-gRNA), sCAT Tg/+ (Et1-gRNA), and +/- (Cas9 protein/Et1-gRNA) vs. +/- (Cas9 mRNA/Et1-gRNA) samples (P = 0.023, 0.001, and 0.042, respectively; Fig. 2d). These results indicate that the mosaic mutation rate of maCas9 zygotes treated with Et1-gRNA alone is lower than that of non-maCas9 zygotes treated with Cas9 mRNA/Et1-gRNA and equivalent to that of non-maCas9 zygotes treated with Cas9 protein/Et1-gRNA (Fig. 2d). Similar results were obtained when another Tyr was examined (Fig. S5d; scAT (Tyr-gRNA) vs. +/- (Cas9 mRNA/Tyr-gRNA); P = 0.037). Furthermore, these results were also confirmed using indel analysis by Inference of CRISPR Edits 2 software (ICE2) (Fig. S6). The rate (%) of mosaicism (presence of three indels or more) of scAT Tg/+ and +/- (Tyr-gRNA) was 34%, which was lower than that of +/- (Cas9 mRNA/Tyr-gRNA) (58%) or +/- (Cas9 protein/Tyr-gRNA) (50%). Thus, the rate of mosaic mutations in maCas9 zygotes (introduced with gRNA alone) may be lower than in non-maCas9 zygotes (introduced with Cas9 mRNA/gRNA).

Similar KI mutation efficiency in maCas9 zygotes and non-maCas9 zygotes transfected with Cas9 mRNA/gRNA or Cas9 protein/gRNA by electroporation. Next, we examined KI mutation efficiency in maCas9 zygotes using gRNA targeted to the Klf5 gene (hereafter referred to as Klf5-gRNA; Fig. 3a,b). maCas9 zygotes were subjected to in vitro EP with 200 ng/µL Klf5-gRNA and 400 ng/µL single-stranded oligodeoxynucleotide (ssODN). Control non-maCas9 zygotes were electroporated with 200 ng/µL Cas9 mRNA, 200 ng/µL Klf5-gRNA, and 400 ng/µL ssODN or 50 ng/µL Cas9 protein, 200 ng/µL Klf5-gRNA, and 400 ng/µL ssODN. Treated embryos were transferred into the oviducts of pseudopregnant females to obtain pups, whose tails were used to extract genomic DNA, which was subjected to genotyping to detect Cas9 transgenes, PCR of the target sequence recognized by Klf5-gRNA, and the restriction fragment length polymorphism assay using the Cla I enzyme. Typical results are shown in Fig. 3c (e.g., #1, #4, and #10). PCR products, obtained using genomic DNA from randomly selected Cla I site-positive mice as PCR template, were sequenced to examine whether ssODNs were correctly knocked-in at the target locus (Fig. 3d). The efficiency of KI mutation in maCas9 zygotes was 48% for Tg/+ pups and 46% for +/- pups (Fig. 3e), with no significant difference. Furthermore, the efficiency of KI mutation generated by using non-maCas9 zygotes into which Cas9 mRNA/gRNA/ssODN or Cas9 protein/gRNA/ssODN had been introduced was slightly lower, 41–44%, which did not show statistical significance (Fig. 3e).

We also examined the generation of KI mutations in maCas9 zygotes by using gRNA targeted to the androgen receptor gene (hereafter referred to as Ar-gRNA; Fig. S7a,b) based on the report of Shen et al., who showed that Ar-gRNA has off-target activity towards at least two genomic loci (3140158–3140172 on chromosome 11 and 121017073–121017287 on chromosome 8; Table S2). To assess the possible off-target activity at these two loci, maCas9 zygotes were subjected to in vitro EP with 100 ng/µL Ar-gRNA and 200 ng/µL ssODN. Control
Figure 2. Comparison of genome editing efficiency in maCas9 and wild-type (WT) zygotes. (a) Schematic of the experimental procedure for examining the efficiency of Et1 gene-editing in maCas9 and WT (non-maCas9) zygotes. (b) Representative 13.5-day post coitum fetuses exhibiting Et1 knockout (KO) and WT phenotypes. Arrows indicate (left panel; KO phenotype) morphological abnormalities of the craniofacial tissue derived from the pharyngeal arch and (right panel; WT phenotype) normal craniofacial tissue. Scale bars indicate 1 mm. (c) Table summarizing the efficiency of Et1 gene-editing observed in maCas9 and WT zygotes after the transfection with exogenous Cas9 mRNA (or protein) and gRNA. (d) Number of indels per genome in Et1 KO fetuses developed from maCas9 zygotes (+/+) and Tg/+ electroporated with 200 ng/µL Et1-gRNAs and non-maCas9 zygotes electroporated with 200 ng/µL Et1-gRNAs and various amounts of exogenous Cas9 mRNA (or protein).
Figure 3. Comparison of knock-in (KI) mutation efficiency in maCas9 and wild-type (WT) zygotes. (a) Schematic of the experimental procedure for examining KI mutation efficiency using Klf5 + flag × 3 ssODN targeting the Klf5 gene. (b) Klf5-gRNA targeting exon 1 of the murine Klf5 gene. The sequence recognized by Klf5-gRNA is shown in blue and the protospacer adjacent motif sequence is shown in red. Arrows indicate the locations of the PCR primers (see Table S5). All Klf5 + flag × 3 ssODN sequences are shown in Table S5. (c) Representative image of agarose gel electrophoresis of PCR products amplified from the genomic DNA of pups (nos. 1–15) obtained from maCas9 zygotes electroporated with 200 ng/µL Klf5-gRNAs and 400 ng/µL ssODN. Top panel: genotyping for the Cas9 gene. Middle and bottom panels: results of the restriction fragment length polymorphism assay using the Cla I enzyme. Pups 1, 4, 5, and 12 were heterozygous for the KI mutation. Pups 10 and 15 were homozygous for the KI mutation. Lanes 1–15 show PCR products amplified from the genomic DNA of all pups; lane WC, PCR product amplified from the genomic DNA of a WT pup; M, lambda HindIII + 100-bp ladder markers. Full-length gel images are presented in Supplementary Information Fig. 3(c). (d) Sequences of 5′ and 3′ junction sites in pup 10. Sequence chromatograms show correct KI of Klf5 + flag × 3 ssODN (Table S5) into exon 1 of the Klf5 gene. (e) Table comparing KI mutation induction efficiency of maCas9-based genome editing and genome editing in WT zygotes after transfection with exogenous Cas9 mRNA (or protein) and gRNA.
non-maCas9 zygotes were electroporated with 100 ng/µL Cas9 mRNA, 100 ng/µL Ar-gRNA, and 200 ng/µL ssODN or 20 ng/µL Cas9 protein, 100 ng/µL Ar-gRNA, and 200 ng/µL ssODN. The treated zygotes were allowed to develop into blastocysts in vitro (Fig. S5a) and then lysed to isolate genomic DNA for PCR-based amplification of the target sequence recognized by Ar-gRNA (Fig. S7b,c) and RFLP assays using BamHI enzyme. Typical KI mutations are shown in Fig. S7c (e.g., #2 and #8). The sequencing results of the PCR products (#8) are shown in Fig. S7d. Blastocysts derived from maCas9 zygotes exhibited KI mutation rate of 8% (Fig. S7e) and off-target activity on chromosomes 8 (genome position 121017073–121017287) and 11 (genome position 3140158–3140172) at mutation rates of 7.9% and 2.8%, respectively (Table S2).

**maCas9 allows efficient simultaneous modification of multiple genes.** We next explored the possibility of using maCas9-based genome editing to simultaneously modify multiple genes. maCas9 zygotes were electroporated with 10 gRNAs for Adm, Amy, Aldh2, Cyp1a1, Et1, Hprt, Klf5, Npr, Ramp1, and Ramp3 (Table S4) at a concentration of 25 ng/µL for each gene (Fig. 4a). Control non-maCas9 zygotes were electroporated in a solution containing the 10 gRNAs mentioned above at concentrations of 25 ng/µL and 50 ng/µL Cas9 protein. The electroporated zygotes were transferred into recipient females to produce pups, with birth rates of 28% (35/127) vs 11% (8/73) for non-maCas9 zygotes electroporated with 25 ng/µL Cas9 mRNA/gRNA (28% = 0.0002; Fig. 4b) vs Cas9 protein/gRNA (41% = 0.004; Fig. 4c). Notably, the number of mice carrying mutations at 8–9 loci was significantly higher for the transferred maCas9 zygotes (Fig. 4d, P = 0.0007), as was the number of mice carrying mutations in 6–7 loci (Fig. 4d, P = 0.0132). To assess possible off-target activities, we examined three possible off-target loci in each of the five genes, Cyp1a1, Et1, Klf5, Npr3, and Hprt, all of which exhibited > 50% on-target activity (Fig. 4e) with no observable mutations in the target regions (Table S3).

Based on these data, we generated GM mice in which three different loci (Et1, Ramp1, and Ramp3) had been simultaneously disrupted (Fig. S8). maCas9 zygotes were electroporated with 25 ng/µL Et1 gRNA, 100 ng/µL gRNA targeted to Ramp1 (hereafter referred to as R1-gRNA), and 100 ng/µL gRNA targeted to Ramp3 (hereafter referred to as R3-gRNA; Fig. S8a). The Et1 gRNA concentration was lowered to 25 ng/µL to avoid possible embryonic lethality caused by a complete loss of Et1 expression34, based on the experiments shown in Figs. 1 and S3. The electroporated zygotes were transferred to pseudopregnant females to produce pups, with a birth rate of 43% (37/86; Fig. S8b). Newborn mice with Tg/+ or +/+ genotypes exhibited high average indel rates for each locus (57% for Et1, 73% for Ramp1, and 59% for Ramp3; Fig. S8b). Genomic DNA was isolated from these pups and genotyped for the presence of Cas9 transgenes. Fig. S8c shows the results of PCR-based amplification of target sequences recognized by each gRNA and a Cas9 ribonucleoprotein (RNP) cut assay for identifying bi-allelic indel mutations. Typical results are shown in Fig. S9. Of the 15 mice tested, 20% (3/15) had indels at three loci, 53% (8/15) at two loci, and 20% (3/15) at one locus. The genomes of the remaining mice (7%, 1/15) were unedited.

**maCas9 zygotes generate more genome-edited pups than WT zygotes co-transfected with Cas9 mRNA/gRNA or Cas9 protein/gRNA.** Notably, maCas9 zygotes delivered a larger number of genome-edited pups than non-maCas9 WT zygotes co-transfected with Cas9 mRNA/gRNA or Cas9 protein/gRNA. For example, maCas9 zygotes electroporated with Et1 gRNA generated more pups than WT zygotes co-transfected with Cas9 mRNA/gRNA (41% vs. 20%, P = 0.014; Fig. 2c) or Cas9 protein/gRNA (41% vs. 23%, P = 0.049; Fig. 2c). A total of 58% of the maCas9 zygotes electroporated with Tyr-gRNA developed into newborn pups, which is higher than the percentage of WT zygotes co-transfected with Cas9 mRNA/gRNA or with Cas9 protein/gRNA (45% and 32%, respectively; Fig. S5c); however, there was no significant difference between these groups. Similarly, in the case of KI mutation induction at the Klf5 locus, maCas9 zygotes generated more newborn pups than non-maCas9 zygotes electroporated with Cas9 mRNA/gRNA (48% vs. 21%, P = 0.004; Fig. 3e) or Cas9 protein/gRNA (48% vs. 20%, P = 0.001; Fig. 3e). When KI mutations were induced at the Ar locus, maCas9 zygotes developed more blastocysts than non-maCas9 zygotes electroporated with Cas9 mRNA/gRNA (69% vs. 15%, P = 0.0002; Fig. S7e) or Cas9 protein/gRNA (69% vs. 8%, P = 0.0001; Fig. S7e). Finally, when 10 gRNAs were introduced simultaneously, maCas9 zygotes developed into viable pups at a greater rate than WT zygotes electroporated with Cas9 protein/gRNAs (28% vs. 11%, P = 0.0001; Fig. 4b).

**Discussion**

The maCas9-mediated generation of genome-edited mice, first reported by us30, can be performed by introducing gRNA alone into maCas9-containing eggs without the need to co-introduce exogenous Cas9 mRNA (or protein). This technology enables multiple target loci in the genome to be edited simultaneously. In this study, we elaborated our previous method by examining the properties of this technology in more detail. In particular, we compared this approach with the most widely used method for the *in vitro* EP-mediated generation of genome-edited mice, which uses a combination of gRNA and Cas9 mRNA (or protein). We found that our system exhibits a comparably high degree of indel mutation efficiency and is superior to the other system due to a low degree of mosaicism, higher KI mutation efficiency, increased pup delivery rate, and the ability to induce mutations in multiple loci simultaneously.

Since we first reported this method30, similar studies have been published by other groups. Zhang et al. generated Tg mice in which Cas9 expression was limited to oocytes during oogenesis under the transcriptional control of the oocyte-specific promoter ZP336. Eggs derived from this Tg line were associated with a lower frequency of mosaicism and a lower occurrence of off-target mutations compared to those observed with conventional methods in which gRNA and Cas9 mRNA are introduced into normal fertilized eggs. However, the system designed by Zhang et al.30 failed to induce KO mutations at a high rate. The authors speculated that this failure was likely
Figure 4. Superiority of maCas9-based genome editing for simultaneously modifying multiple genes in zygotes. (a) Schematic of the experimental procedure for examining the efficiency of simultaneously modifying multiple (10) target loci by genome editing in maCas9 zygotes. The sequences of the 10 target genes are listed in Fig. 4c and Table S4. (b) Table comparing the birth rates of pups developed from maCas9 zygotes electroporated with 10 gRNAs (25 ng/µL each; class A) or non-maCas9 wild-type zygotes electroporated with 10 gRNAs (25 ng/µL each) and 50 ng/µL exogenous Cas9 protein (class B). The Cas9 protein (50 ng/µL) concentration was chosen based on the results presented in Fig. 2c. (c) Indel frequencies for each of the 10 genes in the pups shown in (b). Chr., chromosome number. A > B and A < B indicate whether the indel frequency in class A was higher or lower than that in class B, respectively. (d) Distribution of different indel combinations in class A and class B pups. Values on the graph indicate the percentages of pups with the respective number of simultaneously induced indels.
because the amounts of maCas9 in the immature oocytes were too low. Furthermore, Cebrian-Serrano et al. generated a Tg line carrying a transgene composed of the chicken β-actin-based promoter (CAG), Cas9 gene, and poly(A) site inserted into the Gt(Rosa26)Sor locus35. Using eggs derived from this line, they demonstrated that maCas9-based genome editing induced indels at a level comparable to that achieved with the conventional methods based on the introduction of gRNA and exogenous Cas9 mRNA (or protein) and achieved higher KI mutation efficiency in the target insert. These two reports are generally consistent with our data; however, our results were slightly differently. This discrepancy may have been caused by the use of different gRNAs or promoters to drive Cas9 gene expression, different chromosomal locations of the integrated transgenes, and different genetic backgrounds of the mice, all of which may affect the maCas9 accumulation rate in oocytes. It is difficult to compare the ability to induce genome editing in the target genes of the above-mentioned Cas9-expressing Tg mice. Therefore, in this study we compared the overall genome-edited mouse generation efficiency of our maCas9-based genome editing system using maCas9-expressing Tg mice and the widely used genome editing system based on the introduction of gRNA and Cas9 mRNA (or protein) in-house.

To do so, we used in vitro EP-based gene delivery to introduce genome editing components into fertilized eggs as it is easy to handle, does not require a high degree of manipulator skill, and allows several embryos to be treated at the same time31–34. Having compared the efficiencies of the zygote microinjection method, which is also widely used to generate genome-edited mice, and in vitro EP-mediated gene transfer, we examined whether EGFP A95 mRNA could be introduced into fertilized eggs in a non-biased fashion. The latter technique was found to be better because: 1) embryonic fluorescence intensity did not vary between the groups; and 2) fluorescence intensity was directly proportional to the amount of EGFP A95 mRNA used (Fig. S1). Given that the in vitro EP-based method allows unbiased introduction of a relatively constant amount of gRNA and Cas9 mRNA (or protein) into embryos and is suitable for quantitative analysis, we used this method for transfer in subsequent experiments.

Notably, there was a relationship between the amount of gRNA introduced into maCas9-containing eggs and the number of indels generated per genome (Fig. 1), meaning that the amount of maCas9 was almost equal in each egg. Furthermore, it may be possible to preferentially generate F0 mice with mono-allelic mutations (and bi-allelic mutations) at target loci by controlling the amount of gRNAs used. This could be particularly useful when researchers need to edit a mouse gene whose complete disruption causes embryonic lethality. Indeed, in our study we demonstrated that in vivo EP with maCas9 and a low concentration of gRNA (25 ng/μl) targeting Et1, a gene whose complete KO is known to cause embryonic lethality35,36, preferentially generated pups with mono-allelic mutations (Figs. 1c, S3, and S8).

To evaluate the exact genome editing ability of maCas9 in oocytes, we must consider whether oocytes have Cas9 transgenes or not (so-called Tg/+ oocytes or +/- oocytes). For CAG promoter-containing transgenes, Cas9 transcription and translation in eggs carrying the transgenes occur from the 4-cell stage onward36, often yielding misleading results when maCas9-mediated genome editing activity is evaluated. Zhang et al.37 eliminated the possibility that the Cas9 protein is synthesized from transgenes in their Tg lines during the cleavage stage of embryonic development by using the ZP3 promoter to drive Cas9 expression, which is inactive at the cleavage stage. Cebrian-Serrano et al.37 did not distinguish Tg/+ eggs from +/- eggs when evaluating genome editing efficiency in their Tg lines. In our study, genome editing efficiency of maCas9-containing eggs was not affected by the presence of transgenes (Figs. 1c,d, 2c, and 3e), suggesting that: (1) maCas9, added as a maternal factor during oogenesis, might have been degraded like other general maternal mRNA/proteins before the 2-cell stage37,39; and (2) almost all gRNAs introduced into the zygotes might have been inactivated (and thus degraded) by the time the zygotic genes are activated and de novo Cas9 proteins are translated. Therefore, in subsequent experiments, we analyzed a mixture of +/- and Tg/+ maCas9 zygotes. We also performed immunostaining, but failed to detect maCas9 protein in ovulated oocytes to 8-cell embryos (obtained from sCAT mice), despite using several approaches: DAB-based staining, Alexa 488-based fluorescent staining, the use of different fixation (paraformaldehyde or ethanol), permeabilization (Tween 20 or Triton X100), and blocking (bovine serum albumin or serum) solutions, as well as various commercial available Cas9 antibodies (Diagenode Inc., Belgium, C15200216; TaKaRa BIO Inc., Shiga, Japan, Z2607N) and anti-FLAG tag antibodies (Sigma, F-3165; Transgenics Inc., Kobe, Japan, KO602-S).

In this study, we successfully demonstrated that maCas9-based genome editing efficiently induces KO indels in 55% of +/- individuals and 50% of Tg/+ individuals (Fig. 2), comparable to the genome editing efficiency following the introduction of exogenous Cas9 mRNA (or protein) and gRNA to obtain Et1 KO offspring. In this case, maximum indel induction (as high as 56%) was achieved when exogenous Cas9 protein and gRNA were introduced into WT eggs (Fig. 2), and similar results were obtained when targeting the Tyr gene (Figs. S5 and S6). These results suggest that the enzymatic activity of the exogenously introduced active Cas9 protein (at 50 ng/ μl) is slightly higher than that of maCas9 in sCAT eggs. A similar observation was also made by Zhang et al. (2016), who used eggs derived from the ZP3-Cas9 Tg line for maCas9-based genome editing36. As for the induction of mosaic mutations, our maCas9-based genome editing system caused low mosaicism in Et1 KO offspring and Tyr KO offspring, similar to that observed in the case of a conventional genome editing system with RNP (comprising Cas9 protein and gRNA; Figs. 2d, S5d, and S6b) and consistent with the results of Zhang et al.36 and Cebrian-Serrano et al.37. In contrast, the in vitro EP of WT eggs in the presence of exogenous Cas9 mRNA generated higher ratios of mosaic offspring (see Figs. 2d, S5d, and S6b), potentially due to a delay in the translation or action of the Cas9 protein after introducing Cas9 mRNA into the embryos37,38. The efficiency of KI mutation by the maCas9-based genome editing system using ssODN and gRNA targeting Klf5 tended to be higher than that of genome editing systems based on the introduction of Cas9 mRNA or protein (48% vs. 41% and 44%, respectively; Fig. 3). We also confirmed that KI mutations in the Ar gene were induced in the blastocysts derived from maCas9 zygotes (Fig. S7). Notably, Cebrian-Serrano et al.37 also demonstrated that their maCas9-based genome editing system had a slightly higher KI mutation efficiency (36% vs. 19–30%) than genome editing systems based on the introduction of exogenous Cas9 mRNA (or protein) and gRNA. CRISPR/Cas9-mediated KI events are thought
to occur via HDR-mediated gene replacement or insertion, which are probably not affected by Cas9 molecules enriched in fertilized eggs.

Furthermore, we confirmed that the maCas9-based genome editing system is more efficient than the conventional system based on the introduction of exogenous Cas9 and gRNAs when creating mice with multiple (<10) simultaneous mutations (Fig. 4). We found that the gene-editing ability of maCas9 in sCAT-derived zygotes matched with that observed in WT zygotes electroporated with 100 ng/µL Cas9 mRNA or 50 ng/µL Cas9 protein and gRNA (Figs. 2c and 3e). We also compared the number of target loci simultaneously genome-edited in the F0 pups generated by these two approaches (introducing 50 ng/µL exogenous Cas9 protein with different numbers of gRNAs into WT zygotes for the conventional system). When maCas9-containing eggs were electroporated, we obtained pups with multiple genome-edited loci (Fig. 4c) and a higher number of mice carrying mutations in 8–9 or 6–7 loci simultaneously per individual (Fig. 4d). Thus, the maCas9-based genome editing system appears to be superior for efficiently generating pups with multiple mutated loci by one-step EP in the presence of gRNAs alone. To assess possible off-target effect induction, we examined the off-target activities in five genes proven to exhibit high on-target activities, finding no appreciable off-target mutations in any of the loci screened (Table S3).

Lastly, we found that the number of delivered pups exhibiting both genome editing at a specific locus and simultaneous genome editing at multiple target loci was higher for the maCas9-based genome editing system than for the conventional method based on the introduction of Cas9 mRNA (or protein) and gRNAs (see Figs. 2c, 3e, 4b, 5c and 5e). The lower birth rate in the latter group may be partly due to toxic components included in the synthesized Cas9 mRNA and purchased Cas9 protein products, or due to the upper limit of the amount of Cas9 mRNA/protein introduced into zygotes, because the non-maCas9 zygotes co-transfected with low amounts of Cas9 (15 ng/µL Cas9 mRNA or 5 ng/µL Cas9 protein) yielded similar numbers of delivered pups to the maCas9 zygotes (Fig. 2c). This property is particularly beneficial because it enables analysis of genome-edited F0 mice during the early stages of experiments (Fig. S8).

There are two potential limitations of the maCas9 method based on the use of sCAT mice. First, because the genetic background of sCAT mice is the (BDF 1 × C57Bl/6J) × C57Bl/6J backcross, it is not possible to create gene-modified mice with another background. Therefore, it will be necessary to create a SCAT strain with another common genetic background, such as 129, or obtain a congenic strain by repeated backcrosses. Second, simultaneous multiple gene modifications in maCas9 zygotes derived from sCAT mice are limited to nine sites (Fig. 4), probably due to the limited amount of maCas9 that can be contained in maCas9 zygotes. Therefore, the creation of a sCAT line with higher Cas9 expression is desirable. Our most important finding, however, is that this novel gene-editing system based on the use of maCas9 considerably facilitates the generation of mice with single and multiple gene modifications and could be applied to various animal species other than mice. In addition, similar effects could be obtained using other Cas proteins.

In conclusion, maCas9-based genome editing does not require exogenous Cas9 mRNA (or protein) that has to be prepared in-house or purchased from external companies. The method is also beneficial for producing mice carrying mutations in multiple genes and its efficiency in generating indel and KI mutations is comparable to that of the conventional CRISPR/Cas9-based system for generating genome-edited mice, in which exogenous Cas9 mRNA (or protein) and gRNAs are introduced into WT eggs. Moreover, this novel system features lower mosaicism and higher rates of genome-edited pup delivery than the conventional CRISPR/Cas9-based system. Our sCAT mice will be distributed to the RIKEN BioResource Center (RIKEN, BRC, Tsukuba, Japan), from where these could be purchased by researchers around the world for various experimental purposes.

Methods

Ethics approval for animal experimentation. All animal care and handling procedures were performed in agreement with the guidelines of the Shinshu University Committee on Recombinant DNA Security and approved by the Animal Care and Experimentation Committee of Shinshu University (permit no. 300044).

Mice and zygotes. In this study, we used sCAT (systemically Cas9-expressing Tg) transgenic mouse line and ICR mice. sCAT mice were maintained in-house and PCR-based genotyping for the presence of transgenes was carried out using the Cas9 Tg-1S/Cas9 Tg-1A primer set. Briefly, the candidate target region for each locus was determined using the CRISPRDirect web server (Table S4), and the annealed oligonucleotides for each gene were inserted into the gRNA region of pgRNA_GFP-T1 (#41819; Addgene). Using the resultant vector DNA as a template, the 83-bp PCR products spanning the gRNA scaffold and TTTTTTT site were subcloned into pBluescript II to obtain a pgRNA vector. Using this vector as a template, PCR products containing the T7 promoter sequence were prepared and used for gRNA synthesis using a MEGAl shortcut T7 preparation of genome editing components. To prepare EGFPA95 mRNA, fragments containing EGFp cDNA, a 95 poly(A) stretch, and Sap I sites cloned into the pESA85 vector were amplified by PCR, and the resultant fragments were cloned into the Eco RI sites of pBluescript II (Agilent Technologies Japan, Ltd., Tokyo, Japan) to create pEGFPA95. EGFPA95 mRNA was then synthesized using the mMessage mMachine T3 kit (Ambion, Life Technologies Japan, Ltd., Tokyo, Japan) with Sap I-digested pEGFPA95 as a template. Cas9A95 mRNA was synthesized from Sap I-digested pBS-NFCas9 with a 95 poly(A) stretch as a template. Cas9 protein was purchased from Integrated DNA Technologies, Inc. (IDT; Coralville, Iowa, USA). Eti1, Hprt, Klf5, and Ramp1 gRNAs (Table S4) were the same as those described by Sakurai et al. 35. Adm, Amy, Aldh2, Ar, Cyp1a1, Npr3, and Tyr gRNAs, and R3-gRNA were prepared using the methods described by Sakurai et al. 35. Briefly, the candidate target region for each locus was determined using the CRISPRDirect web server (Table S4), and the annealed oligonucleotides for each gene were inserted into the gRNA region of pgRNA_GFP-T1 (#41819; Addgene). Using the resultant vector DNA as a template, the 83-bp PCR products spanning the gRNA scaffold and TTTTTTT site were subcloned into pBluescript II to obtain a pgRNA vector. Using this vector as a template, PCR products containing the T7 promoter sequence were prepared and used for gRNA synthesis using a MEGAl shortcut T7
transcription kit (Ambion). Klf5 + flagx3 ssODNs (169 bp) and Ar + loxP ssODNs (138 bp) were obtained from IDT as dried materials. The ssODN sequences are shown in Table S5.

Electroporation, embryo transfer, and microinjection. Electroporation was performed with a CUY21EDIT electroporator II (BEX Co., Tokyo, Japan) and platinum electrodes set in a plastic plate (> L501PT1–10; 1 mm gap, 10 mm length, 3 mm width, and 0.5 mm height; BEX Co.) by using the method of Hashimoto and Takemoto with some modifications. A 5 µL drop containing several sets of genome editing components (gRNAs alone; gRNAs and ssODN; gRNAs and Cas9 mRNA; gRNAs, Cas9 mRNA and ssODN; Cas9 RNPs; and Cas9 RNPs and ssODN) in a 1:1 mixture of Opti-MEM (Thermo Fisher Scientific K.K., Tokyo, Japan) and 75% phosphate buffered saline was placed between the electrodes and kept under observation with a dissecting microscope. Cas9 RNPs were prepared by incubating a 1:1 mixture of gRNA(s) and Cas9 protein solutions for 20–30 min at room temperature prior to electroporation. Zygotes (8–30) were placed into the drop, after which EP was carried out at 20 V, switching between on and off for 3 ms and 97 ms, respectively, five times.

Some electroperated eggs were subjected to in vitro cultivation in KSOM up to the 2-cell or blastocyst stage at 37 °C in conditions of 95% humidity and 5% CO2. The remaining embryos were transferred into the oviducts of pseudopregnant ICR females and allowed to develop to the mid-gestational stages (12.5–14.5 dpc) or full-term. Zygote microinjection was performed as described previously using a Narishige-Olympus microinjection system (MMD–202N, MM–89, UT–2, IM–9B, and IX–70; Narishige Group, Ltd., Tokyo, Japan). EGFPA95 mRNA (0–200 ng/µL in 75% phosphate buffered saline) was introduced into both the cytoplasm and pronuclei of the zygotes. The injected eggs were cultivated in KSOM in vitro up to the 2-cell stage.

Fluorescence detection and analysis. EGFPA95 mRNA-derived fluorescence in the electroporated or microinjected embryos was observed using an inverted fluorescence microscope (IX-70; Olympus, Tokyo, Japan) with a U-MWIBA2 filter set (Olympus) and recorded using a DP73 color fluorescence camera (Olympus) under the same exposure and duration conditions. The data were analyzed using ImageJ software (https://imagej.net/User_Guides). Fluorescence was expressed as the average fluorescence in 8–10 embryos per group after deducting background fluorescence intensity.

Analysis of indel, KI, and mosaicism. In this study, we attempted to perform genome editing on a total of 12 loci (Table S4). PCR primers for amplifying regions spanning the mutated sequences are shown in Table S5. The off-target candidates for Ar (Fig. S7), Cyp1A1 (Fig. 4), Et1 (Figs. 2 and 4), Klf5 (Fig. 4), Npr3 (Fig. 4), and Hprt (Fig. 4) were chosen using CRISPRDirect and the top three candidates were analyzed (Table S6). For blastocyst PCR, crude DNA solution prepared from a single blastocyst was genotyped for Cas9 transgenes and PCR was performed on the region recognized by the Et1 gRNA. For obtaining PCR products from mid-gestational fetus or newborn, genomic DNA was isolated from a part of the whole fetus or from a newborn's ear, respectively. To analyze indels, the PCR products were subjected to the T7 endonuclease I-based assay9, direct sequencing, or the Cas9 RNP cut assay (Guide-it Genotype Confirmation kit, Takara Bio Inc., Shiga, Japan). Successful KI of the FLAG × 3 sequence or the loxP KI sequence into the Ar locus was determined by Clal and BamHI digestion of the PCR products generated by amplifying the region recognized by Klf5-gRNA and Ar-gRNA, respectively. Three samples in which the FLAG × 3 sequence or loxP KI sequence had been knocked-in were randomly selected and used to confirm the correct KI of these sequences into the target locus.

To compare the mosaicism of the Et1 and Tyr alleles, the PCR amplicons of KO samples were cloned into the TA cloning vector pMD20 (Takara Bio Inc., Shiga, Japan) for sequencing, according to the manufacturer’s instructions. Approximately 5–8 plasmids per sample were purified, and the possibly mutated locus was sequenced using a BigDye terminator Cycle Sequencing Kit ver3.1 and an ABI Genetic Analyzer 3130 (Applied Biosystems, Foster City, CA, USA). Statistical differences between the experimental and control groups were calculated using two-sided Fisher’s exact tests for a 2 × 2 and 2 × 3 Contingency Table. Differences were considered to be statistically significant if P < 0.05.

Data availability sCAT mice are currently being deposited with the RIKEN BioResource Center (RIKEN, BRC, Tsukuba, Japan; URL: https://ja.brc.riken.jp/), and will be available from the RIKEN BRC in the near future.

References
1. Fellmann, C., Gowen, B. G., Lin, P. C., Doudna, J. A. & Corn, J. E. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nature reviews 16, 89–100 (2017).
2. Vandamme, T. E. Use of rodents as models of human diseases. Journal of pharmacy & biotechnology 6, 2–9 (2014).
3. Behringer, R., Gertsenstein, M., Nagy, K. & Nagy, A. Manipulating the mouse embryo: a laboratory manual. 4th ed. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (2014).
4. Liu, C. & Du, V. eds. Microinjection, Methods and Protocol. Methods in Molecular Biology 1874 Humana press: NY (2019).
5. Fujiw, W., Kawasaki, K., Sugiu, K. & Naito, K. Efficient generation of large-scale genome-modified mice using gRNA and CAS9 endonuclease. *Nucleic acids research* **41**, e187 (2013).

6. Hai, T., Teng, F., Guo, R., Li, W. & Zhou, Q. One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. *Cell research* **24**, 372–375 (2014).

7. Li, D. et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. *Nature biotechnology* **31**, 681–683 (2013).

8. Masahito, D. et al. Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided. RNA. *Scientific reports* **3**, 3355 (2013).

9. Sakurai, T., Watanabe, S., Kaniyosi, A., Sato, M. & Shindo, T. A single blastocyst assay optimized for detecting CRISPR/Cas9 system-induced indel mutations in mice. *BMC biotechnology* **14**, 69 (2014).

10. Shen, B. et al. Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. *Cell research* **23**, 720–723 (2013).

11. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* **153**, 910–918 (2013).

12. Yang, H. et al. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. *Cell* **154**, 1370–1379 (2013).

13. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. *Science New York, NY* **339**, 819–823 (2013).

14. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science New York, NY* **337**, 816–821 (2012).

15. Mali, P. et al. RNA-guided human genome engineering via Cas9. *Science New York, NY* **339**, 823–826 (2013).

16. Burkard, C. et al. Precision engineering for PRRSV resistance in pigs: Macrophages from genome edited pigs lacking CD163 SRCS domain are fully resistant to both PRRSV genotypes while maintaining biological function. *PLoS pathogens* **13**, e1006206 (2017).

17. Crispo, M. et al. Efficient Generation of Myostatin Knock-Out Sheep Using CRISPR/Cas9 Technology and Microinjection into Zygotes. *PLoS one* **10**, e0136690 (2015).

18. Yang, D., Xu, J. & Chen, Y. E. Generation of Rabbit Models by Gene Editing Nucleases. *Methods in molecular biology Clifton, NJ* **1874**, 327–345 (2019).

19. Yoshimi, K., Kaneko, T., Voigt, B. & Mashimo, T. Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR-Cas platform. *Nature communications* **5**, 4240 (2014).

20. Zhou, W. et al. Generation of beta-lactoglobulin knock-out goats using CRISPR/Cas9. *PLoS one* **12**, e0186056 (2017).

21. Piruvell, K. K., Liang, Z. & Wilson, T. E. Repair of double-strand breaks by end joining. *Cold Spring Harbor perspectives in biology* **5**, a012757 (2013).

22. Lieber, M. R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. *Annual review of biochemistry* **79**, 181–211 (2010).

23. San Filippo, J., Sung, P. & Klein, H. Mechanism of eukaryotic homologous recombination. *Annual review of biochemistry* **77**, 229–257 (2008).

24. Oliver, D., Yuan, S., McSwiggin, H. & Yan, W. Pervasive Genotypic Mosaicism in Founder Mice Derived from Genome Editing through Pronuclear Injection. *PLoS one* **10**, e0129457 (2015).

25. Sato, M. et al. Direct Injection of CRISPR/Cas9-Related mRNA into Cytoplasm of Parthenogenetically Activated Porcine Oocytes Causes Frequent Mosaicism for Indel Mutations. *International journal of molecular sciences* **16**, 17838–17856 (2015).

26. Yen, S. T. et al. Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes. *Developmental biology* **393**, 3–9 (2014).

27. Sakurai, T., Shindo, T. & Sato, M. Noninheritable Maternal Factors Useful for Genetic Manipulation in Mammals. *Results and problems in cell differentiation* **63**, 493–510 (2017).

28. Aida, T. et al. Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice. *Genome biology* **16**, 87 (2015).

29. Brinster, R. L., Chen, H. Y., Trumbauer, M. E., Yagle, M. K. & Palmiter, R. D. Factors affecting the efficiency of introducing foreign DNA into mice by microinjection. *Proceedings of the National Academy of Sciences of the United States of America* **82**, 4438–4442 (1985).

30. Sakurai, T. et al. A non-inheritable maternal Cas9-based multiple-gene editing system in mice. *Scientific reports* **6**, 20011 (2016).

31. Hashimoto, M. & Takeo, T. Electroporation enables the efficient mRNA delivery into the mouse zygotes and facilitates CRISPR/Cas9-based genome editing. *Scientific reports* **5**, 11315 (2015).

32. Kanelo, T., Sakuma, T., Yamamoto, T. & Mashimo, T. Simple knockout by electroporation of engineered endonucleases into intact rat embryos. *Scientific reports* **4**, 6382 (2014).

33. Qin, W. et al. Efficient CRISPR/Cas9-Mediated Genome Editing in Mice by Zygote Electroporation of Nucleases. *Genetics* **200**, 423–430 (2015).

34. Kurihara, Y. et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. *Nature* **368**, 703–710 (1994).

35. Shen, B. et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. *Nature methods* **11**, 399–402 (2014).

36. Zhang, L. et al. Generation of an Oocyte-Specific Cas9 Transgenic Mouse for Genome Editing. *PLoS one* **11**, e0154364 (2016).

37. Cebrian-Serrano, R. et al. Maternal Supply of Cas9 to Zygotes Facilitates the Efficient Generation of Site-Specific Mutant Mouse Models. *PLoS one* **12**, e0169887 (2017).

38. Okabe, M., Ikawa, M., Kominami, K., Nakashima, T. & Nishimune, Y. ‘Green mice’ as a source of ubiquitous green cells. *FEBS letters* **407**, 313–319 (1997).

39. Oh, B., Hwang, S., McLaughlin, J., Solter, D. & Knowles, B. B. Timely translation during the mouse oocyte-to-embryo transition. *Development (Cambridge, England)* **127**, 3795–3803 (2000).

40. Singh, P., Schimenti, J. C. & Bolcun-Filas, E. A mouse geneticist’s practical guide to CRISPR applications. *Genetics* **199**, 1–15 (2015).

41. Hur, J. K. et al. Targeted mutagenesis in mice by electroporation of Cp11 ribonucleaseproteins. *Nature biotechnology* **34**, 807–808 (2016).

42. Kim, Y. et al. Generation of knockout mice by Cpf1-mediated gene targeting. *Nature biotechnology* **34**, 808–810 (2016).

43. Naito, Y., Hino, K., Bono, H. & Ui-Tei, K. CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. *Bioinformatics (Oxford, England)* **31**, 1120–1123 (2015).

Acknowledgements

TSA was supported by JSPS KAKENHI Grants (16K15233 and 19K07477) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology. This study was also supported by the Core Research for Revolutionary Science and Technology (CREST), Japan Science and Technology Agency (JST), and Japan Agency for Medical Research and Development (AMED) Core Research for Revolutionary Medical Science and Technology (AMED-CREST).
Author contributions
T.Sa. conceived the study, performed the experiments, and wrote the manuscript. A.K., H.K., S.W. and T.Sh. assisted in conducting the experiments. T.Sa. and M.S. analyzed the data and edited the manuscript. All authors read and approved the final manuscript.

Competing interests
T.Sa. and T.Sh. have filed a patent application relating to the work described in this manuscript. Japan Science and Technology Agency (JST) applied for this patent with an international application “Genetic modification of non-human organisms, egg cells, fertilized eggs, and a method for modifying target genes” (number PCT/ JP2016/085391 filed on November 29, 2016).

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-57996-7.
Correspondence and requests for materials should be addressed to T.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020